Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., Dec. 5, 2023 /PRNewswire/ — Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 14 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed’s Compensation Committee and made as a material inducement to each employee’s entry into employment with the Company.
Related news for (INSM)
- Insmed Reports Second-Quarter 2025 Financial Results and Provides Business Update
- Insmed Announces Pricing of $750 Million Public Offering of Common Stock
- Insmed Announces Proposed $650 Million Public Offering of Common Stock
- Insmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension
- Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update